Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation

doi:10.3877/cma.j.issn.2095-1221.2023.04.007

Abstract

Abstract:

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective method to cure hematological diseases. Thrombocytopenia associated with a poor prognosis is a common but severe complication after allo-HSCT. Blood component transfusion, drugs that promote platelet production and release, and glucocorticoids can treat thrombocytopenia after allo-HSCT, but the efficacy is limited. In recent years, with the study of the pathogenesis of thrombocytopenia after allo-HSCT, mesenchymal stem cells (MSCs) and thrombopoietin receptor agonists (TPO-RA) have been used as their treatment options and have proved to be safe and effective. This article reviews the mechanism of action, safety and efficacy of MSCs combined with TPO-RA in platelet recovery after allo-HSCT.

Key words: Mesenchymal stem cells, Thrombopoietin receptor agonist, Allogeneic hematopoietic stem cell transplantation, Poor graft function, Thrombocytopenia

Wenhui Liu, Tao Wu, Xi Zhang. Advances in mesenchymal stem cells combined with thrombopoietin receptor agonists in platelet recovery after allogeneic hematopoietic stem cell transplantation[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 242-246.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2023.04.007

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2023/V13/I04/242

Figures/Tables 1

References 33

1	王佳丽, 韩明哲. 异基因造血干细胞移植后植入功能不良发生机制研究进展[J].中华血液学杂志, 2019, 40(9):792-795.
2	黄爱杰, 胡晓霞, 王健民. 异基因造血干细胞移植术后血小板减少研究进展[J]. 中国实验血液学杂志, 2017, 25(1):270-275.
3	Zhu L, Liu J, Kong P, et al. Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2022, 13:910893.
4	Huang A, Zhao X, Li M, et al. Suppression of hematopoietic primitive cells in patients with secondary failure of platelet recovery after acute graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2020, 26(10):1840-1854.
5	王恒, 邱婷婷, 徐开林. 异基因造血干细胞移植后继发性血小板减少患者的危险因素及预后意义分析[J]. 徐州医科大学学报, 2022, 42(3):170-174.
6	申彪, 庞爱明, 姜尔烈. 异基因造血干细胞移植后血小板减少发病机制的研究进展[J]. 中国细胞生物学学报, 2022, 44(1):159-164.
7	薛松, 刘夫红, 张永平, 等. 脐血间充质干细胞联合艾曲波帕治疗异基因造血干细胞移植后移植物功能不良的临床研究[J]. 国际输血及血液学杂志, 2022, 45(2):132-139.
8	Man Y, Lu Z, Yao X, et al. Recent advancements in poor graft function following hematopoietic stem cell transplantation[J]. Front Immunol, 2022, 13:911174.
9	Luo Y, Shao L, Chang J, et al. M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion[J]. Blood Adv, 2018, 2(8):859-870.
10	Zhao HY, Lyu ZS, Duan CW, et al. An unbalanced monocyte macrophage polarization in the bone marrow microenvironment of patients with poor graft function after allogeneic haematopoietic stem cell transplantation[J]. Br J Haematol, 2018, 182(5):679-692.
11	Zhao HY, Zhang YY, Xing T, et al. M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity[J]. Signal Transduct Target Ther, 2021, 6(1): 234.
12	Li T, Luo C, Zhang J, et al. Efficacy and safety of mesenchymal stem cells co-infusion in allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis[J]. Stem Cell Res Ther, 2021, 12(1):246.
13	Crippa S, Santi L, Berti M, et al. Role of ex vivo expanded mesenchymal stromal cells in determining hematopoietic stem cell transplantation outcome[J]. Front Cell Dev Biol, 2021, 9:663316.
14	Fathi E, Sanaat Z, Farahzadi R. Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts[J]. Blood Res, 2019, 54(3):165-174.
15	Fathi E, Valipour B, Sanaat Z, et al. Interleukin-6, -8, and TGF-β secreted from mesenchymal stem cells show functional role in reduction of telomerase activity of leukemia cell via Wnt5a/β-catenin and P53 pathways[J]. Adv Pharm Bull, 2020, 10(2):307-314.
16	Diehl R, Ferrara F, Müller C, et al. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches[J]. Cell Mol Immunol, 2017,14(2):146-179.
17	Pinho S, Frenette PS. Haematopoietic stem cell activity and interactions with the niche[J]. Nat Rev Mol Cell Biol, 2019, 20(5):303-320.
18	Prabahran A, Koldej R, Chee L, et al. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation[J]. Blood Adv, 2022, 6(6):1947-1959.
19	Song Y, Zhao HY, Lyu ZS, et al. Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(10):1981-1989.
20	Zhao Y, Gao F, Shi J, et al. Incidence, risk factors, and outcomes of primary poor graft function after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(9):1898-1907.
21	Kong Y, Song Y, Tang FF, et al. N-acetyl-L-cysteine improves mesenchymal stem cell function in prolonged isolated thrombocytopenia post-allotransplant[J]. Br J Haematol, 2018, 180(6): 863-878.
22	Gilreath J, Lo M, Bubalo J. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists[J]. Drugs, 2021, 81(11):1285-1305.
23	Mahat U, Rotz SJ, Hanna R. Use of thrombopoietin receptor agonists in prolonged thrombocytopenia after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(3): e65-e73. doi: 10.1016/j.bbmt.2019.12.003.Epub 2019 Dec 9.
24	Michelson AD, Smolensky Koganov E, Forde EE, et al. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease[J]. J Thromb Haemost, 2018, 16(12):2515-2519.
25	Alvarado LJ, Huntsman HD, Cheng H, et al. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ[J]. Blood, 2019, 133(19):2043-2055.
26	Mei H, Chen X, Zhou J, et al. Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study[J]. Ann Transl Med, 2022, 10(2):30.
27	Servais S, Baron F, Lechanteur C, et al. Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis[J]. Front Immunol, 2023, 14:1106464.
28	Güven ZT, Çelik S, Eser B, et al. Eltrombopag for treatment of thrombocytopenia following hematopoietic stem cell transplantation[J]. Turk J Haematol, 2022, 39(2):103-108.
29	王怡然, 张素平, 李丽, 等. 艾曲泊帕治疗异基因造血干细胞移植后持续性血小板减少的多中心临床研究[J].郑州大学学报(医学版), 2021, 56(2): 253-258.
30	马艳茹, 黄晓军, 莫晓冬, 等. 艾曲波帕治疗异基因造血干细胞移植后难治性血小板减少的临床研究[J].中华血液学杂志, 2016, 37(12):1065-1069.
31	Yan F, Lu N, Gu Z, et al. Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation:a single-center experience[J]. Ann Hematol, 2022,101(2):397-408.
32	刘恩伊,方鹏,信红亚,等. 阿伐曲泊帕治疗异基因造血干细胞移植后血小板减少症疗效与安全性的14例真实世界数据评价[J]. 中南大学学报（医学版）, 2023, 48(3):376-385.
33	Wang M, Feng R, Zhang JM, et al. Dysregulated megakaryocyte distribution associated with nestin+ mesenchymal stem cells in immune thrombocytopenia[J]. Blood Adv, 2019, 3(9): 1416-1428.

参考文献	临床研究病例数	治疗方案	研究结果
Zhu等^[3]	SFPR 13例，PT 3例	阿伐曲泊帕联合MSCs	15例有效
薛松等^[7]	PGF 6例	艾曲泊帕联合MSCs	5例有效
Mahat等^[22]	PIT 78例，SFPR 43例	艾曲泊帕	85例有效
	PIT 17例，SFPR 32例	罗米司亭	40例有效
Güven等^[27]	PT 30例，SFPR 18例	艾曲泊帕	23例有效
王怡然等^[28]	PIT 14例，SFPR 26例	艾曲泊帕	28例有效
马艳茹等^[29]	PT 1例，SFPR 9例	艾曲泊帕	5例有效
Yan等^[30]	PIT 7例，SFPR 27例	艾曲泊帕	22例有效
Liu等^[31]	PIT 8例，SFPR 6例	阿伐曲泊帕	14例有效

参考文献	临床研究病例数	治疗方案	研究结果
Zhu等^[3]	SFPR 13例，PT 3例	阿伐曲泊帕联合MSCs	15例有效
薛松等^[7]	PGF 6例	艾曲泊帕联合MSCs	5例有效
Mahat等^[22]	PIT 78例，SFPR 43例	艾曲泊帕	85例有效
	PIT 17例，SFPR 32例	罗米司亭	40例有效
Güven等^[27]	PT 30例，SFPR 18例	艾曲泊帕	23例有效
王怡然等^[28]	PIT 14例，SFPR 26例	艾曲泊帕	28例有效
马艳茹等^[29]	PT 1例，SFPR 9例	艾曲泊帕	5例有效
Yan等^[30]	PIT 7例，SFPR 27例	艾曲泊帕	22例有效
Liu等^[31]	PIT 8例，SFPR 6例	阿伐曲泊帕	14例有效

[1]	Yangwenxiang Wei, Haoran Huang, Yuhao Liu, Zhenqiu Chen, Haibin Wang, Chi Zhou. Outlooks and challenges in cell therapy of osteonecrosis of femoral head [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 694-700.
[2]	Zhuoyi Fu, Shengcheng Tang, Qiaomei Bu, Gaobing Xu, Anping Wu, Wei Cai, Ming Yang, Haitao Tan. Research progress of magnesium in treatment of osteoarthritis [J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(03): 354-362.
[3]	Zong Shen, Chenru Wei, Banghui Zhu, Yulu Bao, Guosheng Wu, Yu Sun. Advances in animal experiment studies on mesenchymal stem cells for the treatment of inhalation injury [J]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2023, 18(02): 180-183.
[4]	Xin Kong, Baoquan Song, Yin Liu, Jian Zhang, Huiying Qiu, Depei Wu. Intractable hiccup induced by allogeneic hematopoietic stem cell transplantation: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(04): 253-255.
[5]	Yingjun Tang, Huajuan Li, Saini Wang, Wang Xu, Feng Liu, Xi Li, Xinbao Hao, Huaping Huang. Effect and mechanism of human umbilical cord mesenchymal stem cells (HU-MSCs) transplantation on emphysema mice [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 476-480.
[6]	nian Li, Jianjun Zhao, Jianyong Zhang, Ruizhen Zhao. Effect of human amniotic mesenchymal stem cell regulating MAPK signaling pathway of aquaporin 1 in acute lung injury [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(02): 156-163.
[7]	Ye Li, Jie He, Jinxiu Hu, Jinxiang Wang, Chuan Tian, Hang Pan, Mengdie Chen, Xiaojuan Zhao, Li Ye, Min Zhang, Xinghua Pan. Highly active mesenchymal stem cells interfere with ovarian aging in macaques [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 210-219.
[8]	Huiling Long, Mi Lin, Ting Shao. Research progress and application of three-dimensional spherical mesenchymal stem cell culture technology [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 229-234.
[9]	Hongmin Wang, Yunbo Xie, Yanhu Wang, Fusheng Wang. The advance of clinical research in mesenchymal stem cell treatment for COVID-19 [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(04): 247-256.
[10]	Fuhao Qin, Zheng Zheng, Bin Jiang. Research progress of mesenchymal stem cells in the treatment of perianal fifistulizing Crohn's disease [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 172-177.
[11]	Jiuli Yuan, Dan Liu, Linli Li, Jinyu Liu. Basic research and clinical application of hair follicle-derived mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(03): 189-192.
[12]	Xing Feng, Hongtao Jin, Jun Ma, Yongzhou Song, Aijing Liu. Progress in the treatment of inflammatory arthritis with mesenchymal stem cells [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 87-92.
[13]	Shuangyin Lei, Jianxin Xi, Yuxuan He, Jingyi Yao, Boya Shi, Jie Ma, Guangfan Chi, Meiying Li. Applications and advances of mesenchymal stem cells-derived exosomes in treating neurodegenerative diseases [J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(02): 93-100.
[14]	Yunzhao Yang, Cheng Zhou, Meihan Shi, Jing Zhao, Xueyuan Bai. Therapeutic effect of human amniotic fluid-derived mesenchymal stem cells on membranous nephropathy in rats [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 181-186.
[15]	Yanqi Song, Xuejing Ren, Wenjuan Wang, Qiuxia Han, Yue Xu, Kaiting Zhuang, Tuo Xiao, Guangyan Cai. Effect of mesenchymal stem cells on ferroptosis in cisplatin-induced acute kidney injury of mice [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(04): 187-193.

Please choose a citation manager

Content to export